Andy Chen

any preliminary conversations with payers on formulary access? Or early signs that give you confidence on the eventual launch here

can you talk about specific protocol differences between your trial and other trials, especially from IL-17 antibodies?

can you please provide some timing expectation around this diagnosis expansion? Or maybe, in other words, can you maybe speak more regarding the appropriate industry analogs